MARKET

MYMD

MYMD

Mymd Pharmaceuticals Inc
NASDAQ
2.570
-0.190
-6.88%
After Hours: 2.550 -0.02 -0.78% 16:58 02/03 EST
OPEN
2.580
PREV CLOSE
2.760
HIGH
2.780
LOW
2.510
VOLUME
314.88K
TURNOVER
0
52 WEEK HIGH
6.15
52 WEEK LOW
0.9000
MARKET CAP
101.44M
P/E (TTM)
-6.7084
1D
5D
1M
3M
1Y
5Y
Why AppTech Payments Are Trading Lower By Over 25%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Benzinga · 5d ago
NVVE, MYMD and NEON among mid-day movers
Seeking Alpha · 5d ago
12 Health Care Stocks Moving In Tuesday's Intraday Session
Benzinga · 5d ago
Why Heart Test Laboratories Are Trading Higher By 136%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Benzinga · 6d ago
12 Health Care Stocks Moving In Monday's Intraday Session
Benzinga · 6d ago
G Medical, Sharps top healthcare gainers; Quince, Icosavax among losers
Seeking Alpha · 6d ago
MyMD Pharmaceuticals® to Present Data on Oral TNF-a Inhibitor MYMD-1® at the British Society for Immunology (BSI) Congress 2022
BALTIMORE, December 06, 2022--MyMD Pharmaceuticals, Inc.® (Nasdaq: MYMD) ("MyMD" or "the Company"), a clinical stage biopharmaceutical company developing groundbreaking therapies for the treatment of serious and debilitating autoimmune and inflammatory dis...
Business Wire · 12/06/2022 13:00
12 Health Care Stocks Moving In Wednesday's After-Market Session
Benzinga · 11/23/2022 21:32
More
About MYMD
MyMD Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company. The Company is focused on developing and commercializing two therapeutic platforms based on therapeutic targets, MYMD-1 and Supera-CBD. MYMD-1 is a clinical-stage small molecule that regulates the immunometabolic system to treat autoimmune diseases, including multiple sclerosis, diabetes, rheumatoid arthritis, and inflammatory bowel disease. MYMD-1 is being developed to treat age-related illnesses, such as frailty and sarcopenia. MYMD-1 works by regulating the release of numerous pro-inflammatory cytokines, such as TNF-a, interleukin 6 (IL-6) and interleukin 17 (IL-17). Supera-CBD is a synthetic analog of cannabidiol (CBD) being developed to treat various conditions, including epilepsy, pain and anxiety/depression, through its effects on the CB2 receptor, opioid receptors and monoamine oxidase enzyme (MAO) type B. Supera-CBD is also used in treating neuroinflammatory and neurodegenerative diseases.

Webull offers kinds of MyMD Pharmaceuticals Inc stock information, including NASDAQ:MYMD real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, MYMD stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading MYMD stock methods without spending real money on the virtual paper trading platform.